好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Diagnosis and Management of Reversible Cerebral Vasoconstriction Syndrome with a Systemic Rheumatological Disorder: A Case and Updated Review of the Literature
Autoimmune Neurology
P2 - Poster Session 02 (3:00 PM-4:00 PM)
1-063
NA

Reversible cerebral vasoconstriction syndrome(RCVS) mimics primary CNS angiitis. Patients with inflammatory disorders have higher exposure to vasoactive triggers and other factors that can precipitate RCVS, which may lead to more complicated clinical courses. 

We present a complicated case of RCVS with notable history of a rheumatological disorder. Further, we systematically review the literature for RCVS cases with comorbid rheumatological diagnoses to understand the clinical course, triggers and treatment heterogeneity.

A 51-year-old female with SLE vs undifferentiated connective tissue disorder on mycophenolate mofetil and hydroxychloroquine, presented with recurrent thunderclap headaches and focal deficits. She also had a history of mechanical aortic valve requiring aspirin and warfarin, implantable cardioverter-defibrillator, hypertension, depression on fluoxetine, and chronic pain on cannabidiol. CT head demonstrated SAH. CT angiography showed multifocal distal arterial narrowing. CSF and blood analyses were noninflammatory, but MR black-blood imaging was inconclusive. Despite discontinuation of potential offending agents and treatment with oral nimodipine, she deteriorated. Subsequent digital subtraction angiography confirmed the diffuse distal vasoconstriction. Verapamil 10mg was administered in each ICA resulting in angiographic improvement. She had resolution of weakness and returned to her functional baseline within 2 weeks. 

Our systematic review identified 15 prior cases, associated with rheumatologic conditions included SLE, APLA, systemic sclerosis and others. RCVS-PACNS overlap syndrome was also mentioned. Presentations included infarcts, PRES, and hemorrhage. Most patients had triggers including steroids(n=9), immunosuppressants and vasoactive agents. Patients often got serial imaging and increasing doses of calcium channel blockers for variable durations, alongside removal of triggers. However, IA vasodilator therapy was used infrequently.

It is imperative to differentiate RCVS from primary CNS vasculitis. While the mainstay treatment of RCVS is identification of triggers and oral CCBs, we propose that angiography and intra-arterial vasodilators can offer dual diagnostic as well as therapeutic benefits in severe, refractory cases with a neuroimmune overlap.
Authors/Disclosures
Freya S. Kanakhara (UT Houston)
PRESENTER
Ms. Kanakhara has nothing to disclose.
Michael Nahhas, MD (UTHealth Neurosciences Houston - Texas Medical Center) Dr. Nahhas has nothing to disclose.
Robert W. Regenhardt, MD, PhD Dr. Regenhardt has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genomadix. Dr. Regenhardt has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Rapid Medical. Dr. Regenhardt has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Johnson and Bell Trial Lawyers. Dr. Regenhardt has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Buckley, Theroux, Kline, & Cooley Trial Lawyers. The institution of Dr. Regenhardt has received research support from National Institutes of Health. The institution of Dr. Regenhardt has received research support from Society of Vascular and Interventional Neurology. The institution of Dr. Regenhardt has received research support from Heitman Foundation.
Sunil Sheth, MD (University of Texas At Houston) Dr. Sheth has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for Penumbra. Dr. Sheth has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Cerenovus. Dr. Sheth has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Imperative Care.